ACM
LXEO icon

ADAR1 Capital Management’s Lexeo Therapeutics LXEO Stock Holding History

ADAR1 Capital Management’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.29M Buy
1,565,950
+98,600
+7% +$533K 0.33% 71
2026
Q1 		$8.42M Buy
1,467,350
+74,189
+5% +$526K 0.5% 49
2025
Q4 		$13.8M Sell
1,393,161
-138,792
-9% -$1.27M 1.02% 23
2025
Q3 		$10.2M Buy
1,531,953
+1,386,844
+956% +$6.71M 0.96% 24
2025
Q2 		$583K Sell
145,109
-25,339
-15% -$83.3K 0.09% 109
2025
Q1 		$591K Buy
170,448
+943
+0.6% +$4.18K 0.11% 97
2024
Q4 		$1.12M Buy
169,505
+112,339
+197% +$885K 0.22% 73
2024
Q3 		$517K Buy
57,166
+55,866
+4,297% +$666K 0.08% 111
2024
Q2 		$20.9K Buy
+1,300
New +$18.9K ﹤0.01% 218

Other funds holding LXEO

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

ADAR1 Capital Management's LXEO Position: Q2 2026 in Review

ADAR1 Capital Management increased its Lexeo Therapeutics (LXEO) stake by 6.7% in Q2 2026, buying an estimated $533K and bringing the position to 1,565,950 shares worth $7.29M. The position accounts for 0.33% of the portfolio, ranked #71.

ADAR1 Capital Management first reported a position in LXEO in Q2 2024 and has held it in 9 quarters since. The position peaked at $13.8M in Q4 2025. 142 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

  • ADAR1 Capital Management held 1,565,950 shares of Lexeo Therapeutics worth $7.29M as of Q2 2026.
  • ADAR1 Capital Management bought 98,600 Lexeo Therapeutics shares in Q2 2026, an estimated $533K.
  • Lexeo Therapeutics made up 0.33% of ADAR1 Capital Management's portfolio in Q2 2026, its #71 holding.
  • ADAR1 Capital Management first reported a position in Lexeo Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • ADAR1 Capital Management's Lexeo Therapeutics position peaked at $13.8M in Q4 2025.
  • 142 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.